| Identification | Back Directory | [Name]
AZD1152 | [CAS]
722543-31-9 | [Synonyms]
AZD1152
CS-1053
Barasertib (AZD1152)
BARASERTIB; AZD-1152; AZD 1152
5-[[7-[3-[Ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-1H-pyrazole-3-acetamide
1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-
2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | [Molecular Formula]
C26H31FN7O6P | [MDL Number]
MFCD15146330 | [MOL File]
722543-31-9.mol | [Molecular Weight]
587.54 |
| Chemical Properties | Back Directory | [density ]
1.463 | [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [solubility ]
insoluble in H2O; insoluble in EtOH; ≥5.88 mg/mL in DMSO | [form ]
solid | [pka]
1.75±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Barasertib. is a selective inhibitor of Aurora B kinase, which inhibits human tumor xenograft growth by inducing apoptosis. | [Definition]
ChEBI: AZT-1152 is a dihydrogen phosphate prodrug of a pyrazoloquinazoline aurora kinase inhibitor AZD1152-hydroxyquinazoline pyrazol anilide(HQPA) and is converted rapidly to the active AZD1152-HQPA in plasma. It has a role as a prodrug, an antineoplastic agent and an Aurora kinase inhibitor. It is a member of quinazolines, a monoalkyl phosphate, an anilide, a member of monofluorobenzenes, a member of pyrazoles, a secondary amino compound, a secondary carboxamide and a tertiary amino compound. It is functionally related to an AZD-1152. | [in vivo]
Barasertib (AZD1152, 25 mg/kg) markedly suppresses the growth and weights of AZD1152-treated tumors[1].
Barasertib (AZD1152, 5 mg/kg) enhances the ability of vincristine or daunorubicin to inhibit the proliferation of human MOLM13 leukemic xenografts[1].
Barasertib (AZD1152, (10-150 mg/kg/d) potently inhibited the growth of human colon, lung, and hematologic tumor xenografts (mean tumor growth inhibition range, 55% to z100%; P < 0.05) in immunodeficient mice[2].
| Animal Model: | Female immune-deficient BALB/c nude mice (MOLM13 cells injected)[1]. | | Dosage: | 5 or 25 mg/kg. | | Administration: | Intraperitoneal injection 4 times a week or every another day. | | Result: | Inhibited the growth of human MOLM13 cells growing as xenografts using an immunodeficient murine model. |
| [IC 50]
Aurora B: 0.37 nM (IC50) |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|